Imbio to be Acquired by 4DMedical Creating Comprehensive Cardiothoracic Image Analysis Portfolio

Acquisition by global medical company advances powerful analytical imaging technology

0
39

Summation

  • (a portfolio company of Minneapolis-based Invenshure LLC), a provider of medical imaging analysis technologies for chronic lung and cardiothoracic diseases, announces it has entered a binding agreement to be acquired by 4DMedical, a leading producer of advanced lung function imaging software.
  • “Imbio is very excited to join forces with 4DMedical to create the leading lung imaging AI suite in the market, combining 4DMedical’s functional analysis with Imbio’s anatomical and tissue analysis.
  • Partnering with 4DMedical to create a unified offering and platform will maximize patient impact and shareholder value,” said Danny Cunagin, Chairman of Imbio and Co-CEO of Invenshure.

Imbio, Inc. (a portfolio company of Minneapolis-based Invenshure LLC), a provider of medical imaging analysis technologies for chronic lung and cardiothoracic diseases, announces it has entered a binding agreement to be acquired by 4DMedical, a leading producer of advanced lung function imaging software. The combined technology offering will turn any standard chest CT into a much broader Cardiothoracic Analysis, immediately providing functional, structural, and risk-based analysis for both lung and heart disease.

Imbio’s technology provides quantitative and personalized imaging analysis for patients with acute and chronic diseases. The automated system transforms chest CT studies into visual lung maps, generating detailed reports on abnormalities. Imbio algorithms support various clinical initiatives, including lung cancer screening, smoking cessation, surgical planning, and pulmonary embolism management. Additionally, they are leveraged in clinical trials and academic research for diverse diseases.

Imbio is very excited to join forces with 4DMedical to create the leading lung imaging AI suite in the market, combining 4DMedical’s functional analysis with Imbio’s anatomical and tissue analysis. Together we can help clinicians around the globe detect disease earlier, make more robust diagnosis, and drive more informed and confident decision-making for better patient care,” said Dave Hannes, CEO at Imbio.

“This merger represents the culmination of a multi-year effort by Invenshure to create and build Imbio into a preeminent healthcare technology company. Partnering with 4DMedical to create a unified offering and platform will maximize patient impact and shareholder value,” said Danny Cunagin, Chairman of Imbio and Co-CEO of Invenshure.

“I am extremely excited to join forces with the incredibly talented and committed Imbio team. Imbio’s market-leading suite of AI solutions provide life-changing insights from CT scans, and perfectly complements 4DMedical’s functional imaging technology,” says Andreas Fouras, Founder and CEO of 4DMedical. “We now offer a comprehensive cardiothoracic imaging solution set to providers and their patients. Importantly, the Imbio acquisition also boosts our commitment to improve veteran pulmonary health care—especially for those impacted by toxic exposures during service.”